Dainippon Sumitomo: Pipeline, Products, Performance, Potential

Summary

Dainippon Sumitomo Pharma (DSP) is a research-based pharmaceutical company, headquartered in Osaka, which has resulted from the merger of Dainippon Pharmaceutical (which acts as the surviving company) and Sumitomo Pharmaceutical (a division of Sumitomo Chemical). This new strategic analysis report provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products.

The merger was finalised and operations began on 1st October 2005, with the new company becoming the fifth largest pharmaceutical company in Japan. DSP is listed as a consolidated subsidiary of Sumitomo Chemical, which owns 50.1 per cent of the outstanding shares.

Since the merger, DSP is active in a range of therapeutic areas, principally Cardiovascular; Oncology/ Infection; Gastrointestinal; Central Nervous System (CNS); Inflammation/Allergy; and Diabetes. In the future, DSP intends to focus its product base on CNS diseases and the treatment of diabetes and associated complications.

This new strategic analysis report Dainippon Sumitomo: Pipeline Products Performance Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

Contents

• Executive Summary
  • A Detailed And Comprehensive Overview Of Current Financial Position, Company Strategy, Product And Pipeline Analysis.
• Therapeutic Area Focus
  • Key Product Analysis And Forecasting
  • Neuroscience
  • Cymbalta/Xeristar (Duloxetine)
  • Zyprexa (Olanzapine)
  • Endocrine Diseases
  • Actos (Pioglitazone)
  • Byetta (Exenatide)
  • Evista (Raloxifene)
  • Forto/Forteo/Forsteo (Teriparatide)
  • Humalog (Insulin Lispro)
  • Oncology
  • Alimta (Pemetrexed Disodium)
  • Gemzar (Gemcitabine)
  • Cardiovascular
  • Cialis (Tadalafil)
  • Effient (Prasugrel)
• Operational Data
  • A Wealth Of Background And Detail
  • A Full 5-Year Financial Performance Assessment
  • Key Agreements
  • Infrastructure
  • Subsidiaries And Joint Ventures